New tumor suppressor microRNAs target glypican-3 in human liver cancer
- PMID: 28476031
- PMCID: PMC5522324
- DOI: 10.18632/oncotarget.17162
New tumor suppressor microRNAs target glypican-3 in human liver cancer
Abstract
Glypican-3 (GPC3) is an oncogene, frequently upregulated in liver malignancies such as hepatocellular carcinoma (HCC) and hepatoblastoma and constitutes a potential molecular target for therapy in liver cancer. Using a functional screening system, we identified 10 new microRNAs controlling GPC3 expression in malignant liver cells, five of them e.g. miR-4510, miR-203a-3p, miR-548aa, miR-376b-3p and miR-548v reduce GPC3 expression. These 5 microRNAs were significantly downregulated in tumoral compared to non-tumoral liver and inhibited tumor cell proliferation. Interestingly, miR-4510 inversely correlated with GPC3 mRNA and protein in HCC samples. This microRNA also induced apoptosis of hepatoma cells and blocked tumor growth in vivo in the chick chorioallantoic membrane model. We further show that the tumor suppressive effect of miR-4510 is mediated through direct targeting of GPC3 mRNA and inactivation of Wnt/β-catenin transcriptional activity and signaling pathway. Moreover, miR-4510 up-regulated the expression of several tumor suppressor genes while reducing the expression of other pro-oncogenes. In summary, we uncovered several new microRNAs targeting the oncogenic functions of GPC3. We provided strong molecular, cellular and in vivo evidences for the tumor suppressive activities of miR-4510 bringing to the fore the potential value of this microRNA in HCC therapy.
Keywords: cancer; glypican-3; hepatocellular carcinoma; liver; microRNA.
Conflict of interest statement
The authors disclose no potential conflicts of interest.
Figures








Similar articles
-
The Role of microRNAs in Regulating Cancer Cell Response to Oxaliplatin-Containing Regimens.Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231206003. doi: 10.1177/15330338231206003. Technol Cancer Res Treat. 2023. PMID: 37849311 Free PMC article. Review.
-
A functional screening identifies five microRNAs controlling glypican-3: role of miR-1271 down-regulation in hepatocellular carcinoma.Hepatology. 2013 Jan;57(1):195-204. doi: 10.1002/hep.25994. Hepatology. 2013. PMID: 22865282
-
HOXA-AS2 Promotes Proliferation and Induces Epithelial-Mesenchymal Transition via the miR-520c-3p/GPC3 Axis in Hepatocellular Carcinoma.Cell Physiol Biochem. 2018;50(6):2124-2138. doi: 10.1159/000495056. Epub 2018 Nov 9. Cell Physiol Biochem. 2018. PMID: 30415263
-
miR-4510 blocks hepatocellular carcinoma development through RAF1 targeting and RAS/RAF/MEK/ERK signalling inactivation.Liver Int. 2020 Jan;40(1):240-251. doi: 10.1111/liv.14276. Epub 2019 Oct 31. Liver Int. 2020. PMID: 31612616
-
Down-regulating glypican-3 expression: molecular-targeted therapy for hepatocellular carcinoma.Mini Rev Med Chem. 2014;14(14):1183-93. doi: 10.2174/1389557515666150101105135. Mini Rev Med Chem. 2014. PMID: 25553423 Review.
Cited by
-
Diagnostic Value of Glypican-3 for Hepatocellular Carcinomas.Asian Pac J Cancer Prev. 2018 Mar 27;19(3):811-817. doi: 10.22034/APJCP.2018.19.3.811. Asian Pac J Cancer Prev. 2018. PMID: 29582639 Free PMC article.
-
Characterization of an Activated Metabolic Transcriptional Program in Hepatoblastoma Tumor Cells Using scRNA-seq.Int J Mol Sci. 2024 Dec 4;25(23):13044. doi: 10.3390/ijms252313044. Int J Mol Sci. 2024. PMID: 39684755 Free PMC article.
-
miR-216a-3p Inhibits the Proliferation, Migration, and Invasion of Human Gastric Cancer Cells via Targeting RUNX1 and Activating the NF-κB Signaling Pathway.Oncol Res. 2018 Jan 19;26(1):157-171. doi: 10.3727/096504017X15031557924150. Epub 2017 Aug 23. Oncol Res. 2018. PMID: 28835317 Free PMC article.
-
The Role of microRNAs in Regulating Cancer Cell Response to Oxaliplatin-Containing Regimens.Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231206003. doi: 10.1177/15330338231206003. Technol Cancer Res Treat. 2023. PMID: 37849311 Free PMC article. Review.
-
Children's Oncology Group's 2023 blueprint for research: Liver tumors.Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30576. doi: 10.1002/pbc.30576. Epub 2023 Jul 26. Pediatr Blood Cancer. 2023. PMID: 37495540 Free PMC article.
References
-
- Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015;12:436. - PubMed
-
- von Schweinitz D. Hepatoblastoma: recent developments in research and treatment. Semin Pediatr Surg. 2012;21:21–30. - PubMed
-
- Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, Kamel IR, Ghasebeh MA, Pawlik TM. Hepatocellular carcinoma: From diagnosis to treatment. Surg Oncol. 2016;25:74–85. - PubMed
-
- Zynger DL, Gupta A, Luan C, Chou PM, Yang GY, Yang XJ. Expression of glypican 3 in hepatoblastoma: an immunohistochemical study of 65 cases. Hum Pathol. 2008;39:224–230. - PubMed
-
- Capurro MI, Xiang YY, Lobe C, Filmus J. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res. 2005;65:6245–6254. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical